CDK4/6 inhibitor selection eLearning
Barbara, Juanita and Emma have all been diagnosed with HR+/HER2- metastatic breast cancer and have been prescribed a CDK4/6 inhibitor. Can you help us select the optimal CDK4/6 inhibitor for each of our three patients?
This content has been developed independently of the sponsor, Lilly, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.